Thomas Aagaard Rasmussen

This early-stage study is testing whether adding the cancer drug venetoclax to standard HIV treatment when a person first starts therapy can help. The goal is to see if venetoclax helps the body eliminate more of the cells that hide inactive HIV, potentially reducing the 'reservo…